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Brief Definit ive Report
B cell maturation starts in the bone marrow but 
is completed in the spleen (Hardy et al., 2007). 
Survival of IgM+ splenic B cells is linked to the 
antiapoptotic B cell lymphoma 2 (BCL2) fam-
ily of proteins and their opposing proapoptotic 
antagonist, BCL2-interacting mediator of cell 
death (BIM; Enders et al., 2003), and depends 
on “tonic” signals from surface IgM and IgD 
B cell antigen receptors transmitted through 
spleen tyrosine kinase (SYK), Bruton’s tyrosine 
kinase (BTK), and phosphatidylinositol 3 ki-
nase (Srinivasan et al., 2009). Starting from the 
transitional 2 (T2) stage, B cells also depend on 
survival signals provided by a circulating cyto-
kine, B cell–activating factor (BAFF), engaging 
the BAFF receptor (BAFFR; Khan, 2009). 
BCRs and BAFFR signal via pathways that ac-
tivate transcription factors of the NF-B fam-
ily, and these play essential roles in mediating 
survival of B cells (Siebenlist et al., 2005).
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Druggable proteins required for B lymphocyte survival and immune responses are an 
emerging source of new treatments for autoimmunity and lymphoid malignancy. In this 
study, we show that mice with an inactivating mutation in the intramembrane protease 
signal peptide peptidase–like 2A (SPPL2A) unexpectedly exhibit profound humoral 
immunodeficiency and lack mature B cell subsets, mirroring deficiency of the cytokine 
B cell–activating factor (BAFF). Accumulation of Sppl2a-deficient B cells was rescued 
by overexpression of the BAFF-induced survival protein B cell lymphoma 2 (BCL2) but 
not BAFF and was distinguished by low surface BAFF receptor and IgM and IgD B cell 
receptors. CD8-negative dendritic cells were also greatly decreased. SPPL2A deficiency 
blocked the proteolytic processing of CD74 MHC II invariant chain in both cell types, 
causing dramatic build-up of the p8 product of Cathepsin S and interfering with earlier 
steps in CD74 endosomal retention and processing. The findings illuminate an impor-
tant role for the final step in the CD74–MHC II pathway and a new target for protease 
inhibitor treatment of B cell diseases.
© 2013 Bergmann et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncommercial– 































Published December 24, 2012
32 Survival of B cells and CD8 DCs requires SPPL2A | Bergmann et al.
RESULTS AND DISCUSSION
B cell deficiency and humoral immunodeficiency  
in Sppl2a-deficient mice
Flow cytometric screening of blood from ENU-mutagenized 
mouse pedigrees identified an otherwise normal strain with 
decreased B cells and very low expression of IgD on the IgMlow 
subset of mature B cells (Fig. 1 A). Meiotic mapping in 
(B6xCBA)F2 mice located the causative mutation to a 13-Mb 
interval between rs6401493 and rs3726475 on Chr2 (not de-
picted), whereas exome and whole genome sequencing re-
vealed a mutation within the interval at position 2 in intron 7 
of the Sppl2a gene (Fig. 1 B). The mutation caused complete 
skipping of exon 7 in the mRNA, introducing a frameshift 
and premature stop codon that deleted most of the SPPL2A 
protein, including seven of the nine transmembrane domains 
and the protease active site (Fig. 1 B). Retroviral transduction 
of IL-7–cultured mutant pre-B cells with wild-type Sppl2a 
cDNA but not with empty vector restored normal IgD ex-
pression on B cells that matured in vitro (Fig. 1 C), confirm-
ing the causative role for the truncating mutation in Sppl2a.
Homozygous mutant animals had 25-fold less serum IgM 
and sixfold less IgG1 (Fig. 1 D). Almost no specific antibody 
was made after immunization with formalin-inactivated and 
heat-killed Bordetella pertussis and alum-precipitated chicken 
gamma globulin (CGG) coupled to p-azobenzenearsonate 
(ABA) hapten or after immunization with the T-independent 
antigen 4-hydroxy-3-nitrophenylacetyl-Ficoll (NP-Ficoll; 
Fig. 1 E). Thus, SPPL2A is essential for normal B cell matura-
tion and humoral immunity.
SPPL2A is required for accumulation of mature B cells  
in secondary lymphoid tissues
Analysis of B cell maturation in the bone marrow of Sppl2a 
mutant mice showed normal cellularity (not depicted), nor-
mal numbers of pro-B, pre-B, and immature B cells, and nor-
mal cell surface IgM and normal onset of IgD expression 
among the IgMhigh T1 subset (Fig. 2 A). Mature IgD+IgMlow 
recirculating B cells were selectively decreased in the bone 
marrow and had very low surface IgD. In the spleen, the T1 
subset of recent bone marrow emigrants (CD93+IgMhighCD23) 
was present in normal numbers and expressed levels of surface 
IgM comparable with controls (Fig. 2, B and C). Subsequent 
maturational stages of T2, T3, and mature CD93IgMlow B cells 
were 20-fold reduced, whereas the mature marginal zone 
B cell subset was decreased 200-fold. Immunofluorescent 
staining of spleen sections showed that the residual B cells in 
SPPL2A-deficient mice nevertheless localized normally in 
primary follicles (Fig. 2 D). This developmental block resem-
bles that caused by deficiency of BAFF or BAFFR, and we 
therefore directly compared Sppl2a mutants with BAFF-
deficient animals, the latter serving as a control to distinguish 
unique traits caused by SPPL2A deficiency from general ef-
fects of mature B cell deficiency. Both defects manifested at 
the same developmental stage, but CD23 induction during 
B cell maturation, which appears to reflect NF-B signaling 
(Sasaki et al., 2006), was even lower in SPPL2A-deficient than 
CD74, also called MHC II invariant chain or Ii, is a type 2 
transmembrane protein with an enigmatic role in B cell 
survival. CD74 has a well-established function in antigen 
presentation: it forms nonameric complexes with nascent 
MHC II molecules, shields the MHC II peptide–binding 
groove against premature peptide binding, and directs MHC II 
to endocytic compartments where exogenous antigens are 
processed into MHC II–binding peptides (Villadangos et al., 
1999). CD74–MHC II complexes reach endocytic compart-
ments via transient appearance at the plasma membrane and 
rapid clathrin-mediated endocytosis (Dugast et al., 2005; 
McCormick et al., 2005). Once in endosomes, the lumenal 
domain of CD74 undergoes a series of C-terminal proteolytic 
cleavages (Villadangos et al., 1999). Cathepsin S is required in 
B cells and DCs for the penultimate CD74 cleavage, which 
releases the class II invariant chain peptide (CLIP) and an 8-kD 
N-terminal transmembrane CD74 peptide that appears to be 
rapidly processed by an unknown intramembrane-cleaving 
protease (Villadangos et al., 1999; Matza et al., 2002b).
An unexpected finding in Cd74 knockout mice was the oc-
currence of a modest block at the transitional stage in B cell 
development, characterized by a failure to up-regulate IgD and 
CD23 normally in H2b (Shachar and Flavell, 1996) but not in 
H2k mouse strains (Zimmermann et al., 1999). One line of evi-
dence indicated this defect was caused by the absence of the final 
CD74 cleavage product: an unstable cytosolic N-terminal 42-aa 
peptide with NF-B–promoting activity (Matza et al., 2002b). 
In contrast, two parallel studies indicated that deficiency of 
CD74’s MHC II chaperone activity was responsible for the fail-
ure to accumulate mature B cells normally (Benlagha et al., 
2004; Maehr et al., 2004). Hence the role of regulated intra-
membrane proteolysis in B cell maturation remains unresolved.
Regulated intramembrane proteolysis (Wolfe, 2009) is 
best known from the role of presenilin (-secretase) in 
Alzheimer’s disease and in Notch signaling for T cell matura-
tion and leukemia (Selkoe and Kopan, 2003). Transmembrane 
protein substrates are first cleaved to release their extracellu-
lar domain by an ectoprotease, followed by a second intra-
membrane cleavage mediated by presenilin or signal peptide 
peptidase (SPP) enzymes that are amenable to pharmacolog-
ical inhibition (Wolfe and Kopan, 2004; Eder et al., 2007). 
SPPL2A is an endosome/lysosome-localized member of 
the SPP-like (SPPL) intramembrane cleaving aspartyl pro-
teases (aspartyl I-CliPs; Behnke et al., 2011). SPPL2 prote-
ases specifically degrade single pass, type II transmembrane 
proteins, and in vitro studies have identified several poten-
tial SPPL2A substrates, such as British precursor protein 2 
(BRI2; Martin et al., 2008), membrane FAS ligand (Kirkin 
et al., 2007), and membrane TNF (Friedmann et al., 2006), 
but so far a biological role for SPPs remains largely un-
known. In this study, we identify an N-ethyl-N-nitrosourea 
(ENU)–induced mouse mutant strain lacking SPPL2A and 
define a nonredundant function for SPPL2A in CD74 pro-
cessing and the expression of survival receptors on B cells, 
revealing a critical role for regulated intramembrane prote-
olysis in B cells and DCs.
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cell surface IgD and 30% of normal IgM, leading to a profound 
decrease in their surface BCR pool. The inability of SPPL2A-
deficient B cells to maintain normal levels of surface IgM was 
also apparent in the mature B1 B cell subset in the peritoneal 
cavity, which were also reduced in numbers (not depicted).
Bcl2 rescues B cell accumulation
The low BCR and BAFFR could prevent T2 and mature B cells 
from receiving tonic survival signals needed to suppress the 
BCL2-associated X protein (BAX)/BCL2 antagonist killer 
(BAK) mitochondrial apoptosis pathway, or conversely acti-
vation of this pathway could prevent normal BCR and 
BAFFR expression. To diminish mitochondrial apoptosis, the 
Sppl2a/ strain was crossed with Vav-Bcl2-Tg mice overex-
pressing the BAX/BAK inhibitor BCL2. In the resulting 
Sppl2a/ Vav-Bcl2 offspring (Fig. 3), enforced BCL2 expression 
increased the total number of splenic B cells to 32.2 ± 15 × 
106 (mean and SD), which was greater than the number in 
wild-type mice (19.5 ± 4.6 × 106) or in Sppl2a/ mice (9.4 ± 
3.7 × 106). The numbers in Sppl2a/ Vav-Bcl2 mice were 
in BAFF-deficient mice (Fig. 2 B). Analysis of bone marrow 
chimeras confirmed that mature B cell deficiency was cell 
autonomous and could not be rescued by overexpression of 
BAFF in animals receiving Sppl2a/ marrow (not depicted).
BAFFR levels on the B cell surface normally increase 
during maturation from the T1 to the T2 and mature stage, 
and this was also observed in BAFF-deficient mice (Fig. 2 E). 
In contrast, in the absence of SPPL2A, there was almost no 
up-regulation of BAFFR at either the T2 or mature stage of 
B cell development, resulting in receptor levels that were 
25% of normal on mature CD93 B cells, even when the 
latter were further resolved from immature B cells by gating 
on CD62L+CD93 mature B cells (Fig. 2, E and F). Surface 
expression of IgD followed the same pattern as BAFFR 
(Fig. 2 F). Conversely, cell surface expression of IgM decreased 
progressively from T1 to the mature B cell stage in wild-type 
mice, and this measure of B cell maturation was not disrupted 
in BAFF-deficient mice and was even more pronounced in 
SPPL2A-deficient animals (Fig. 2 E). As a result, the residual 
mature B cells in SPPL2A-deficient mice had 12% of normal 
Figure 1. Humoral immunodeficiency in Sppl2a/ mice. (A) Percentage of CD19+ B cells among blood lymphocytes and representative IgM/IgD 
flow cytometric plots gated on CD19+ B cells from mice of the indicated genotypes. Numbers in top left corner are geometric mean fluorescence intensity 
of IgD, and other numbers are percentage of cells in each gate. ****, P < 0.0001. (B) Schematic of Sppl2a splice-donor mutation, the resulting skipping of 
exon 7, and the effect on the SPPL2A protein. (C) Surface IgD on GFP+IgM+ Sppl2a/ B cells from IL-7 bone marrow cultures transduced with a retroviral 
vector encoding wild-type SPPL2A and GFP (thick line) or empty vector encoding GFP alone (thin line), compared with Sppl2a+/+ B cells transduced with 
empty GFP vector (shaded gray). (D) ELISA analysis of total serum IgM and IgG1 in unimmunized animals. (E) ELISA analysis of serum antibodies to  
B. pertussis and CGG 2 wk after immunization, against the ABA 4 wk after immunization, and against NP-Ficoll 6 d after booster immunization. Bars rep-
resent the mean, and each symbol represents a single mouse. Data are representative of more than five experiments with at least three animals per group 
in each (A), one experiment (B and C) or two (D), and one experiment with at least five to seven mice per group (E).
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Figure 2. Mature Sppl2a/ B cells fail to up-regulate BAFFR or IgD and do not accumulate in the periphery. (A) Representative flow cyto-
metric plots and percentages of bone marrow B cell subsets from homozygous mutant and wild-type mice. (B) Representative flow cytometric plots 
and percentages of spleen B cell subsets from Sppl2a/, Baff/, and wild-type (Sppl2a+/+) mice. (C) Number of cells of the indicated subsets in 
spleens from Sppl2a/, Baff/, and Sppl2a+/+ mice: Lympho, lymphocytes; Foll, follicular B cells; MZ, marginal zone B cells. Bars show mean, and 
each symbol is a single mouse. (D) Spleen cryosections from Sppl2a+/+ and Sppl2a/ mice were stained with fluorescently labeled antibodies to de-
tect B cells (CD19) and T cells (CD3). Bars, 200 µm. (E) Mean fluorescence intensity (MFI) of staining for BAFFR, IgD, and IgM on the indicated B cell 
subsets in spleens from Sppl2a/, Baff/, and Sppl2a+/+ mice. (F) Representative flow cytometric staining presented as overlay histograms for B220, 
IgM, IgD, BAFFR, and CD23 on Sppl2a+/+ (shaded gray) and Sppl2a/ (black line) immature (CD62LlowCD93high) or mature (CD62LhighCD93low) splenic  
B cells. The numbers show the MFI for Sppl2a+/+ (gray; top) and Sppl2a/ cells (black; bottom). Data are representative of at least three experiments 
with three mice (A–C and E), two experiments with one to three mice per group (D), or one experiment with three mice per group (F). Pregates for 
FACS plots are indicated above each column.
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transgenic mice. Likewise, these studies have shown that BCL2 
does not substitute for B cell maturation signals delivered by 
these receptors, and this may contribute to the lower propor-
tion of CD93 and CD62L+ cells in Sppl2a/ Vav-Bcl2 mice. 
Nevertheless, in the spleen of Sppl2a mutant mice, Vav-Bcl2 in-
creased the number of CD93IgMlow mature B cells by 6.5-fold 
but did not alter the numbers of CD93+IgMhigh T1 B cells 
(Fig. 3, A and B). The ratio of mature to immature B cells was also 
increased by BCL2, when measured comparing CD93IgMlow 
nevertheless lower than in Vav-Bcl2-Tg mice with wild-type 
SPPL2A (107 ± 42 × 106), indicating that rescue of B cell ac-
cumulation by BCL2 did not render the B cells independent 
of the need for SPPL2A. BCL2 slows but does not inactivate 
BAX/BAK-induced B cell apoptosis upon withdrawal of sur-
vival signals (Takeuchi et al., 2005), and consequently BAFFR 
deficiency (Rahman and Manser, 2004), BAFF blockade 
(Tardivel et al., 2004), or acute loss of the BCR (Lam et al., 1997) 
each diminishes the accumulation of mature B cells in Bcl2 
Figure 3. Overexpression of antiapoptotic BCL2 in Sppl2a/ mice rescues accumulation of mature B cells. (A) Representative flow cyto-
metric plots of lymphocytes in the spleen from mice of the indicated Sppl2a and Vav-Bcl2 genotypes. Pregates for plots are indicated above the col-
umns. (B) Number of B cells of the indicated subsets in spleens from Sppl2a+/+ and Sppl2a/ mice, either transgenic for Vav-Bcl2 or not. Bars show 
mean, and each symbol is a single mouse. (C) Representative flow cytometric plots of CD62L and CD93 expression on B cells from subcutaneous LNs 
in Vav-Bcl2 transgenic mice of the indicated genotype. Overlay of flow cytometric histograms for B220, IgM, IgD, BAFFR, and CD23 cell surface ex-
pression on CD62LhighCD93low mature B cells in spleen (top) or LNs (bottom) from Sppl2a+/+ (shaded gray) and Sppl2a/ (black line) mice. Numbers in 
the plots indicate geometric mean fluorescence intensity for Sppl2a+/+ (gray; top) and Sppl2a/ cells (black; bottom). Data are representative of one 
to three experiments with three to four mice per group (A and C) or combined from four experiments (B).
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mice have fewer IgDhigh B cells (Shachar and Flavell, 1996; 
Benlagha et al., 2004; Maehr et al., 2004). Western blotting 
with an antibody to the CD74 N terminus revealed an ac-
cumulation of 12- and 9-kD fragments in spleen B cells 
from Sppl2a/ mice and a slight accumulation in heterozy-
gotes (Fig. 4 A). In contrast, there was no reduction in the 
expression of the full-length p31 and p41 isoforms of CD74 
(Fig. 4 A) and a small increase in cell surface expression of 
full-length CD74 and MHC II on immature and mature B cells 
(Fig. 4 B). Western blotting of lysates from sorted CD11c+ 
splenic DCs revealed that SPPL2A deficiency also caused a 
striking accumulation of 9- and 12-kD CD74 N-terminal 
fragments (Fig. 4 C), corresponding to the predicted sizes 
for the penultimate p8 and p10 cleavage products produced 
with CD93+IgMhigh or comparing CD93CD62L+ with CD93+ 
CD62L. In contrast, Vav-Bcl2 failed to correct the low cell 
surface levels of BAFFR, IgM, and IgD on the accumulating 
CD93 B cells in either the spleen or the LNs (Fig. 3 C), in-
dicating that the failure to display these receptors on the cell 
surface is not secondary to apoptosis.
Proteolytic processing of CD74 requires SPPL2A
Despite ubiquitous Sppl2a expression in the immune system 
(Heng et al., 2008), we observed a B cell–specific pheno-
type in mice lacking SPPL2A. To identify possible SPPL2A 
targets, we performed a bioinformatic search for type II trans-
membrane proteins up-regulated during B cell maturation. 
CD74 was a particularly good candidate as CD74-deficient 
Figure 4. Proteolytic processing and intra-
cellular retention of CD74 requires SPPL2A. 
(A) Immunoblot analysis of splenic B cells from 
Sppl2a/, Sppl2a+/, and Sppl2a+/+ mice. Blots 
were probed with In-1 antibody against the CD74 
N-terminal tail and then stripped and reprobed 
with antibody to /-Tubulin. p41 and p31 iso-
forms of CD74 are indicated. (B) Flow cytometric 
staining for cell surface MHC II and CD74 on 
splenic B220+CD93+ immature and B220+CD93 
mature B cells from Sppl2a+/+ (shaded gray) and 
Sppl2a/ mice (black line). (C) Immunoblot analy-
sis of splenic B cells and the non-DC/non-B cell 
(Non) fraction from Sppl2a/ and Sppl2a+/+ mice 
probed as for A. (D) Schematic diagram of CD74 
processing steps and products, showing esti-
mated molecular mass (kilodaltons) and proteases 
involved. (E) Flow cytometric staining for cell 
surface MHC II and CD74 on splenic CD11c+ DCs 
from Sppl2a+/+ (shaded gray) and Sppl2a/ mice 
(black line). Numbers in the plots indicate geo-
metric mean fluorescence intensity (MFI). (F) Flow 
cytometric light SSC as a relative measure of cell 
vesicle content, gated on IgMhigh immature and 
IgD+ mature B cells in the blood as shown in the 
left panel of plots from Sppl2a+/+ and Sppl2a/ 
mice. Bars show mean, and each symbol is data 
from one mouse. P-value from one-way ANOVA 
with Bonferroni’s Multiple Comparison posttest: 
*, P = 0.01–0.05. Data are representative of one 
experiment (A–C) or at least three experiments 
with three or more mice per group (E and F).
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This appears ruled out for three reasons. First, there was much 
greater loss of T2 and mature B cells in SPPL2A deficiency 
than CD74 deficiency. Second, CD74 deficiency rescued ac-
cumulation of T2 and mature B cells in Sppl2a mutant mice 
(see accompanying papers in this issue by Beisner et al. and 
Schneppenheim et al. [2013]), establishing that loss of SPPL2A 
protease activity accounts for the B cell developmental defect 
via accumulation of unprocessed CD74. Third, the residual B cell 
deficiency in mice lacking CD74 was corrected in Cd74/Ia/ 
double-deficient mice, implying that unchaperoned MHC II 
by Cathepsin S in DCs and B cells (Fig. 4 D). The extraordi-
nary accumulation of the p8 penultimate cleavage product re-
veals SPPL2A as the previously unknown peptidase responsible 
for this final cleavage of CD74 (Lipp and Dobberstein, 1986).
Sppl2a/ DCs also had a dramatic accumulation of larger 
CD74 N-terminal fragments of 16, 18, and 22 kD that cor-
respond to early Cathepsin-dependent stages in proteolytic 
processing of the CD74 ectodomain and a small increase in 
full-length CD74 p31 and p41 proteins (Fig. 4 C). Flow cyto-
metric staining with an antibody to the full-length CD74 
C-terminal domain nevertheless revealed a 20-fold increased 
accumulation on the cell surface of SPPL2A-deficient DCs, 
whereas MHC II levels were modestly increased (Fig. 4 E). 
The large increase in cell surface CD74 suggests a failure of 
this molecule to traffic to acidified endosomes. A secondary 
effect of SPPL2A deficiency on endosomal trafficking could 
account for the accumulation of partially processed 16-, 18-, 
and 22-kD products because these require processing of the 
CD74 ectodomain by cathepsin S and other proteases in 
acidified endosomes. Accumulation of trimerized CD74 p8 
can distort the endosomal system by inducing large intracel-
lular early endosomes with delayed maturation into late en-
dosomes and lysosomes (Lagaudrière-Gesbert et al., 2002). 
As an objective measure of intracellular vacuolation, we used 
flow cytometry to measure the side scatter (SSC) of laser light 
in peripheral blood B or T cells. SSC was significantly in-
creased selectively in mature IgD+IgMlow B cells from Sppl2a/ 
mice compared with littermate controls (Fig. 4 F), and this 
was not observed in BAFF-deficient controls (not depicted). 
These data complement electron microscopic observations of 
increased cytoplasmic vacuoles in the accompanying paper in 
this issue by Schneppenheim et al. and show that this B cell 
abnormality arises at the transition from IgD to IgD+ B cells 
and is not accounted for by increased apoptosis.
Sppl2a/ animals have few CD8 DCs
Having shown that SPPL2A was essential for CD74 process-
ing in DCs, we investigated the accumulation of splenic DC 
subsets. Sppl2a/ mice had fewer CD11c+ DCs (Fig. 5 A) as 
the result of only 12% of normal numbers in the CD4+ and 
the CD4CD8 double-negative (DN) DC subsets, whereas 
CD8+ and plasmacytoid DCs were present at normal and in-
creased numbers, respectively (Fig. 5, B and C). Less CD11c 
and CD8 was present on the B220CD8+ DCs in Sppl2a/ 
animals (Fig. 5 B). Thus, SPPL2A is also critical for key pop-
ulations of antigen-presenting DCs. The DC deficit may also 
contribute to the profound humoral immunodeficiency ob-
served in animals lacking the enzyme.
Our results identify SPPL2A as the long-sought protease 
responsible for the final step in CD74 invariant chain process-
ing and reveal its critical role in B and DC accumulation. 
A key question arising from our findings is how SPPL2A defi-
ciency results in Bcl2-inhibitable loss of B cells. One explanation 
is failure to release the CD74 p4 intracellular domain, which 
can serve as a transcriptional coactivator for NF-B and B cell 
maturation (Matza et al., 2002a; Becker-Herman et al., 2005). 
Figure 5. Sppl2a is critical for CD8 DCs. (A and B) Representative 
flow cytometric plots of total spleen cells (A) or spleen DCs (B) from 
Sppl2a/, Sppl2a+/, and Sppl2a+/+ mice. Pregates for plots are indi-
cated above each column. (C) Number of cells in each DC subset in 
spleens from mice of the indicated genotypes. cDC, conventional DCs; 
pDC, plasmacytoid DCs; DN, CD4 and CD8 DN DCs; CD43+, pre-DCs 
gated as per middle column plots in B. Bars show mean, and each sym-
bol represents a single mouse. Data are representative of three experi-
ments with at least three mice per group (A) or two experiments with 
one to three mice per group (B and C).
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the manufacturer’s instructions. cDNA was synthesized using the Super-
Script First Strand Synthesis System (Invitrogen) using oligo (dT) primers. 
PCR amplification of parts of the Sppl2a cDNA used primers in exon 5 
(5-CCATCCTGGCCTAACTTTGA-3) and exon 9 (5-CATGAAA-
TTGGGTAACTTCATTGT-3) and AccuPrime High Fidelity Taq 
(Invitrogen). After gel purification, PCR products were sequenced on an 
ABI 3730 Sequencer (Applied Biosystems).
Flow cytometry and Western blotting. Spleen and bone marrow cells 
were prepared, stained, and analyzed by flow cytometry according to pub-
lished methods (Yabas et al., 2011). For DC isolation, DC-enriched light den-
sity fractions of spleens were used for analysis as described previously (Aliberti 
et al., 2003). In brief, spleens were injected with warmed Collagenase D 
(Roche)–RPMI (Invitrogen) and incubated for 30 min at 37°C, after which 
all steps were performed at 0–4°C. After collagenase incubation, spleens were 
forced through cell strainer followed by several washes in EDTA-PBS, before 
cell suspension was layered over 30% BSA-PBS, and centrifuged for 15 min at 
500 g. The resulting interface was collected and stained for DC analysis by flow 
cytometry, using antibodies mentioned below, including lineage markers 
CD19, TCR, TCR/, CD90.2, Ter119, and NK1.1.
Samples were analyzed using an LSR II or LSRFortessa flow cytometer 
or sorted using a FACSAria II cell sorter (BD). For analysis or sorting, the 
following antibodies (clones) were used and purchased from the indicated 
companies. From BD: anti-CD3 (145-2C11), anti-CD4 (RM4-5), anti-CD8 
(53-6.7), anti-CD19 (1D3), anti–CD21-CD35 (7G6), anti-CD23 (B3B4), 
anti-CD43 (S7), anti-CD45.2 (104), anti-B220 (RA3-6B2), anti-CD90.2 
(53–2.1), anti–TCR-/ (GL3), anti–Gr-1 (RB6-8C5), anti-IgM (II/41), 
anti-NK1.1 (PK136), and anti-CD11c (HL3). From eBioscience: anti-CD5 
(53–7.3), anti-CD8 (53–6.7), anti-CD19 (eBio1D3), anti-CD93 (AA4.1), 
anti-B220 (RA3-6B2), anti-IgD (11-26), anti-IgM (II/41), and anti-Ter119 
(TER-119). From BioLegend: anti-CD3 (17A2), anti–CD21-CD35 (7E9), 
anti-CD23 (B3B4), anti-CD24 (M1/69), anti-CD43 (1B11), anti-CD45.1 
(A20), anti-IgD (11-26c.2a), anti–Mac-1 (M1/70), anti-TCR (H57-597), 
and anti-BAFFR (7H22-E16). From Invitrogen: 7-AAD and Qdot 605 
streptavidin conjugate. From Santa Cruz Biotechnology, Inc.: goat anti–rabbit 
IgG and F(ab). Anti–CD74-JV11 rabbit polyclonal serum was a gift from 
J.A. Villadangos (University of Melbourne, Melbourne, Victoria, Australia).
For Western blotting, sorted B cells, DCs, and non-B cell–DC fractions 
were counted and resuspended at equal cell numbers in 2-mercaptoethanol 
containing SDS sample buffer, incubated at 37°C for 60 min, sonicated at 
intervals to achieve 15 min of total sonication time, separated by Tricine 
SDS-PAGE on 16% acrylamide gel with 6% cross-linking, and transferred to 
nitrocellulose membrane. For immunoblotting and detection of N-terminal 
CD74 and /-Tubulin, antibodies from BD (In-1) and Cell Signaling Tech-
nology were used.
Immunofluorescence microscopy. 10-µm spleen cryosections were fixed 
in acetone and blocked with 5% pig serum, before detecting B cell follicles and 
T cell zones with anti–mouse CD19-PE (1D3) and anti–mouse CD3-FITC 
(145-2C11) antibodies from BD. Slides were analyzed on an IX 71 fluores-
cence microscope (Olympus).
Statistical analysis. Data were statistically analyzed using Prism 5.0d for Mac 
OS X (GraphPad Software). For comparison of multiple groups, ANOVA 
with Bonferroni’s Multiple Comparison posttest was used.
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inhibits B cell maturation in CD74-deficient mice (Zimmermann 
et al., 1999; Benlagha et al., 2004; Maehr et al., 2004).
Interference with intracellular trafficking may explain the 
defects observed here. In mature B cells, MHC II and full-
length CD74 are primarily on the cell surface until the BCR 
is engaged by antigen. BCR signals induce CD74 association 
with myosin light chain kinase and activate CD74-dependent 
formation of large, perinuclear, MHC II–rich intracellular ves-
icles containing processed CD74 p10, BCRs, and partially pro-
cessed antigen (Siemasko et al., 1998; Zimmermann et al., 
1999; Kim et al., 2006; Vascotto et al., 2007). In the absence of 
SPPL2A, the accumulation of CD74 p8 or p12 trimers in ma-
ture B cells may modify endosomal trafficking to interfere with 
IgM, IgD, and BAFFR transport or recycling to the cell surface, 
depriving the B cells of survival signals. The selective depen-
dence of mature B cells and DC subsets on functional SPPL2A 
and the existence of pharmacological inhibitors of SPPL pro-
teases (Eder et al., 2007) make this enzyme an interesting drug 
target for immunosuppression, particularly for B cell malignan-
cies that often express high levels of CD74 (Stein et al., 2007).
MATERIALS AND METHODS
Mice and procedures. Sppl2a and Tnfsf13b (BAFF) mutant strains were 
identified by flow cytometry screening of blood lymphocytes in third gener-
ation offspring of C57BL/6 mice treated with 3 × 90 mg/kg ENU. The 
Tnfsf13b nonsense mutation converts Tyrosine 27 codon (TAT) to STOP 
(TAA). Bone marrow chimeras and immunizations were performed as de-
scribed previously (Yabas et al., 2011). All ENU mutant mice were gener-
ated and maintained on a C57BL/6 background, and the Rag1/ and 
Vav-Bcl2-Tg were backcrossed for at least 10 generations to the C57BL/6 
background. For all mouse experiments, littermate controls were used. All 
mice were housed in specific pathogen–free conditions at the Australian 
National University Bioscience Research Services facility, and all animal proce-
dures were approved by the Australian National University Animal Ethics 
and Experimentation Committee.
For retroviral transduction, mouse Sppl2a cDNA was cloned into pMXs-
IRES-EGFP (provided by T. Kitamrua, The University of Tokyo, Tokyo, 
Japan) and transduced into retroviral producer cell line GP+E86 (a gift from 
D. Vignali, St. Jude Children’s Research Hospital, Memphis, TN). MACS-
purified B220+ B cells from bone marrow were cultured in 10 ng/ml IL-7 
(R&D Systems) for 2 d and co-cultured with retroviral producer cells for 48 h 
in the presence of IL-7 and Polybrene (Sigma-Aldrich). The cells were washed, 
cultured for 8 d with 10 ng/ml BAFF (R&D Systems) and without IL-7 to 
facilitate B cell maturation, and analyzed by flow cytometry.
Exome and whole genome sequencing. A fragmented Illumina library 
was prepared from the DNA of a single affected mouse using the Illumina 
paired end genomic DNA sample pre kit (Illumina). Exome capture of this 
library was then performed using Agilent Mouse SureSelect kit (early access) 
according to protocol v1, September 2009, and the DNA was sequenced on 
a GAIIx sequencer (Illumina). Alignment to the UCSC mm9 assembly of 
the reference mouse genome and SNP calling and filtering were performed 
as described previously (Andrews et al., 2012). Whole genome 100-bp 
paired-end sequencing of a single affected mouse was performed on an Illu-
mina HiSeqII machine to a mean coverage depth of 3.4x. Reads were 
mapped to the MGSCv37 mouse genome using Stampy and an in-house 
variant caller (www.well.ox.ac.uk/platypus) and filtered for known variants 
in dbSNP or other ENU pedigrees in addition to quality, strand bias, and 
coverage filters using in-house python scripts.
cDNA sequencing. Total RNA was isolated from splenic lympho-
cytes using the mirVana micro RNA isolation kit (Ambion) according to 
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